It’s only fair to share… Palacaparib CAS 2756333-39-6 MFC21H22F2N6O2 MW428.4 g/mol 6-fluoro-5-[4-[(5-fluoro-2-methyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N-methylpyridine-2-carboxamide 2-Pyridinecarboxamide, 6-fluoro-5-(4-((5-fluoro-3,4-dihydro-2-methyl-3-oxo-6-quinoxalinyl)methyl)-1-piperazinyl)-N-methyl- 6-fluoro-5-{4-[(5-fluoro-2-methyl-3-oxo-3,4-dihydroquinoxalin-6-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamidepoly (ADP-ribose) polymerase (PARP) inhibitor, antineoplastic, AZD 9574, 9UG32UQW48 Palacaparib is an investigational new drug that is being evaluated by AstraZeneca for the treatment of prostate cancer.[1] It is a selective PARP1 inhibitor.[2][3] Palacaparib (also known as AZD9574) is an investigational, orally bioavailable cancer drug developed by AstraZeneca. It belongs to …
Category «Uncategorized»
Zidesamtinib
It’s only fair to share… Zidesamtinib CAS 2739829-00-4 MF C22H22FN7O MW419.5 g/mol (19R)-3-ethyl-16-fluoro-10,19-dimethyl-20-oxa-3,4,9,10,11,23-hexazapentacyclo[19.3.1.02,6.08,12.013,18]pentacosa-1(25),2(6),4,8,11,13(18),14,16,21,23-decaen-22-amine To treat adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer after receiving a ROS1 kinase inhibitor FDA 2026, APPROVALS 2026, Jideytro, NVL-520, NUV-520, NU-520, NVL 520, NUV 520, NU 520, MX5KQV5XHC Zidesamtinib (sold under the brand name Jideytro) is an …
Gedatolisib
It’s only fair to share… Gedatolisib Approvals 3026, FDA 2026, 7/14/2026, Revtorpyk PF-05212384; PF-5212384; PKI-587CAS 1197160-78-3Chemical Formula: C32H41N9O4Molecular Weight: 615.721-(4-{[4-(Dimethylamino)-1-piperidinyl]carbonyl}phenyl)-3-{4-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]phenyl}urea3-{4-[bis(morpholin-4-yl)-1,3,5-triazin-2-yl]phenyl}-1-{4-[4-(dimethylamino)piperidine-1-carbonyl]phenyl}ureaN-[4-[[4-(Dimethylamino)-1-piperidinyl]carbonyl]phenyl]-N’-[4-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]phenyl]ureaгедатолисиб [Russian] [INN]غيداتوليسيب [Arabic] [INN]吉达利塞 [Chinese] [INN] 1-(4-(4-(Dimethylamino)piperidine-1-carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)urea Urea, N-[4-[[4-(dimethylamino)-1-piperidinyl]carbonyl]phenyl]-N’-[4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl]- 96265TNH2R In combination with fulvestran, to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment …
Ontunisertib
It’s only fair to share… Ontunisertib CAS 2647949-48-0 MFC27H21F2N5O MW469.5 g/mol N-[(2,6-difluorophenyl)methyl]-2-[3-(6-methyl-2-pyridinyl)-4-quinolin-4-ylpyrazol-1-yl]acetamide N-(2,6-difluorobenzyl)-2-(3-(6-methylpyridin-2-yl)-4-(quinolin-4-yl)-1H-pyrazol-1-yl)acetamide N-[(2,6-difluorophenyl)methyl]-2-[3-(6-methylpyridin-2-yl)-4-(quinolin-4-yl)-1H-pyrazol-1-yl]acetamideserine/threonine kinase inhibitor, AGMB 129, SF6HGC94LK Ontunisertib (AGMB-129) is an experimental, orally active small-molecule drug developed by Agomab Therapeutics to treat Fibrostenosing Crohn’s Disease (FSCD). It acts as a highly selective inhibitor of ALK5 (also known as Transforming Growth Factor-beta type I receptor …
Olisutrigine bromide
It’s only fair to share… Olisutrigine bromide Cas 1393836-45-7 MF C25H35BrN2 MW443.5 g/mol N-[2-[(2R)-1,1-dimethylpiperidin-1-ium-2-yl]ethyl]-N-(2-methylphenyl)-2,3-dihydro-1H-inden-2-amine bromide (2R)-2-{2-[N-(2,3-dihydro-1H-inden-2-yl)-2-methylanilino]ethyl}-1,1-dimethylpiperidin-1-ium bromidesodium channel blocker, analgesic, ASN008, ASN 008, EN 3427, 0M9Q318030 Olisutrigine bromide (also known as ASN-008 or EN3427) is an investigational, permanently charged sodium channel blocker being studied for its potent, long-lasting analgesic (pain-relieving) properties. Key Characteristics Current Status A …
Netanasvir
It’s only fair to share… Netanasvir CAS 2007900-70-9 MF C51H58N8O7 MW895.1 g/mol methyl N-[(1R)-2-[(2S,4S)-2-[5-[7-[2-[(2S,5S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]-5-methylpyrrolidin-2-yl]-3H-benzo[e]benzimidazol-7-yl]-2,3-dihydro-1H-inden-4-yl]-1H-imidazol-2-yl]-4-(methoxymethyl)pyrrolidin-1-yl]-2-oxo-1-phenylethyl]carbamate antiviral, Dongweizhuo, HCV, Antaitavir Hasophate, HEC 74647 PA, 4Y7YD32BYY Netanasvir (commonly prescribed as netanasvir phosphate) is a direct-acting antiviral medication primarily used to treat chronic hepatitis C virus (HCV) infection. It was approved by the China National Medical Products Administration (NMPA) under the …
Nelremagpran
It’s only fair to share… Nelremagpran CAS 2492595-24-9 MFC15H9ClF4O3 MW 348.67 g/mol 3-[[2-Chloro-4-(trifluoromethyl)phenoxy]methyl]-2-fluorobenzoic acid 3-{[2-chloro-4-(trifluoromethyl)phenoxy]methyl}-2-fluorobenzoic acidMas-related G protein-coupled receptor inverse agonist, anti-inflammatory, MRGPRX4 modulator-2, BL83FAK6DZ, Nelremagpran is an experimental drug that acts as a potent and selective antagonist (or possibly inverse agonist) of the MAS-related Gq protein-coupled receptor X4 (MRGPRX4). It has antiinflammatory effects in animal studies. This receptor …
Nedizantrep
It’s only fair to share… Nedizantrep CAS 2376824-99-4 MF C20H19ClN6O3 MW 426.9 g/mol 1-[[3-[(3R,5R)-5-(4-chlorophenyl)oxolan-3-yl]-1,2,4-oxadiazol-5-yl]methyl]-2,7-dimethylpurin-6-one 1-({3-[(3R,5R)-5-(4-chlorophenyl)oxolan-3-yl]-1,2,4-oxadiazol-5-yl}methyl)-2,7-dimethyl-1,7-dihydro-6Hpurin-6-onetransient receptor potential (TRP) ion channel antagonist, GDC-6599, GDC 6599, RG 6341, RG-6341, ENQ95FVE4X Nedizantrep (also known by its developmental code GDC-6599) is a potent, selective, and orally active chemical compound developed as a transient receptor potential ankyrin 1 (TRPA1) cation channel …
Navlimetostat
It’s only fair to share… Navlimetostat CAS 2630904-45-7 ALSO 2630904-44-6 MF C23H18ClFN6O2 MW464.9 g/mol (2M)-2-{4-[4-(aminomethyl)-1-oxo-1,2-dihydrophthalazin-6-yl] -1-methyl-1H-pyrazol-5-yl}-4-chloro-6-(cyclopropyloxy)-3-fluorobenzonitrileantineoplastic, MRTX-1719, BMS-986504, MRTX 1719, BMS 986504 Navlimetostat (also known as MRTX-1719 or BMS-986504) is an investigational, first-in-class oral targeted cancer therapy being developed by Bristol-Myers Squibb. It works by selectively binding to the PRMT5-MTA complex, exploiting synthetic lethality to kill …
Moxetomidate
It’s only fair to share… Moxetomidate CAS 1567838-90-7 MF C15H18N2O3 MW 274.31 g/mol 2-methoxyethyl 3-[(1R)-1-phenylethyl]imidazole-4-carboxylate 2-methoxyethyl 1-[(1R)-1-phenylethyl]-1H-imidazole-5-carboxylateGABAA receptor agonist, hypnotic, ET-26, ET 26, LPQ2K767W2 Moxetomidate (also known as methoxyetomidate or ET-26) is a novel, investigational short-acting intravenous anesthetic and sedative-hypnotic agent. It functions as a{GABA}_A} receptor agonist and is designed as a “soft drug” analogue of …